Stock HUGE FSD PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Market Closed - Canadian Securities Exchange
Other stock markets
 20:59:29 14/05/2024 BST 		5-day change 1st Jan Change
0.485 CAD 0.00% Intraday chart for FSD Pharma Inc. -6.73% -59.58%
05-07 FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia CI
04-30 FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
CI
FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication
CI
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement
MT
FSD Pharma Receives Nasdaq Non-Compliance Notice
MT
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO
MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd
CI
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum
CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma
MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million
MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million
MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
MT
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
MT
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp.
CI
FSD Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
FSD Pharma Enters Agreement on Distribution of Portion of Celly Nutrition Shareholdings
MT
FSD Pharma Inc. agreed to Spin-Off 34.66% stake of Celly Nutrition Corp.
CI
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
CI
FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023
CI
FSD Pharma Inc. Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HUGE Stock
  4. News FSD Pharma Inc.
  5. Highlights